Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls.
antipscychotic medication
brain network
fMRI
network science
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
04
2019
accepted:
31
07
2019
entrez:
2
10
2019
pubmed:
2
10
2019
medline:
2
10
2019
Statut:
epublish
Résumé
The study of brain networks, including those derived from functional neuroimaging data, attracts a broad interest and represents a rapidly growing interdisciplinary field. Comparing networks of healthy volunteers with those of patients can potentially offer new, quantitative diagnostic methods and a framework for better understanding brain and mind disorders. We explore resting state functional Magnetic Resonance Imaging (fMRI) data through network measures. We construct networks representing 15 healthy individuals and 12 schizophrenia patients (males and females), all of whom are administered three drug treatments: i) a placebo; and two antipsychotic medications ii) aripiprazole and iii) sulpiride. We compare these resting state networks to a performance at an "N-back" working memory task. We demonstrate that not only is there a distinctive network architecture in the healthy brain that is disrupted in schizophrenia but also that both networks respond to antipsychotic medication. We first reproduce the established finding that brain networks of schizophrenia patients exhibit increased efficiency and reduced clustering compared with controls. Our data then reveal that the antipsychotic medications mitigate this effect, shifting the metrics toward those observed in healthy volunteers, with a marked difference in efficacy between the two drugs. Additionally, we find that aripiprazole considerably alters the network statistics of healthy controls. Examining the "N-back" working memory task, we establish that aripiprazole also adversely affects their performance. This suggests that changes to macroscopic brain network architecture result in measurable behavioral differences. This is one of the first studies to directly compare different medications using a whole-brain graph theoretical analysis with accompanying behavioral data. The small sample size is an inherent limitation and means a degree of caution is warranted in interpreting the findings. Our results lay the groundwork for an objective methodology with which to calculate and compare the efficacy of different treatments of mind and brain disorders.
Identifiants
pubmed: 31572229
doi: 10.3389/fpsyt.2019.00611
pmc: PMC6752631
doi:
Types de publication
Journal Article
Langues
eng
Pagination
611Subventions
Organisme : Medical Research Council
ID : MR/K020706/1
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Towlson, Vértes, Müller-Sedgwick and Ahnert.
Références
J Neurosci. 2010 Jul 14;30(28):9477-87
pubmed: 20631176
Neuroimage. 2012 Apr 15;60(3):1759-70
pubmed: 22209809
PLoS One. 2011;6(9):e25423
pubmed: 21980454
Cereb Cortex. 2013 Jul;23(7):1509-16
pubmed: 22645252
Transl Psychiatry. 2018 Apr 24;8(1):87
pubmed: 29686254
Front Hum Neurosci. 2015 May 26;9:296
pubmed: 26074803
Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Feb;67(2 Pt 2):026126
pubmed: 12636767
Nat Rev Neurosci. 2003 Oct;4(10):829-39
pubmed: 14523382
Hum Brain Mapp. 2011 May;32(5):800-11
pubmed: 21484950
Nat Rev Neurosci. 2009 Mar;10(3):186-98
pubmed: 19190637
Cereb Cortex. 2013 Jan;23(1):127-38
pubmed: 22275481
Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11747-52
pubmed: 19564605
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9604-9609
pubmed: 31004051
PLoS Comput Biol. 2007 Feb 2;3(2):e17
pubmed: 17274684
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Nature. 1998 Jun 4;393(6684):440-2
pubmed: 9623998
Eur Neuropsychopharmacol. 2010 Aug;20(8):519-34
pubmed: 20471808
Neuroimage. 2020 Oct 15;220:116611
pubmed: 32058004
Neuroimage. 2005 Feb 1;24(3):810-21
pubmed: 15652316
Phys Rev E Stat Nonlin Soft Matter Phys. 2008 Mar;77(3 Pt 2):036104
pubmed: 18517458
Biomed Res Int. 2014;2014:915026
pubmed: 24772438
Neuroimage Clin. 2017 May 14;15:439-448
pubmed: 28616384
Neuroimage. 2012 Oct 1;62(4):2296-314
pubmed: 22387165
NPJ Schizophr. 2016 Apr 27;2:16014
pubmed: 27336056
Neuroimage. 2006 May 15;31(1):197-208
pubmed: 16431137
Psychopharmacology (Berl). 2013 May;227(2):221-9
pubmed: 23271192
Neuroimage. 2010 Apr 15;50(3):970-83
pubmed: 20035887
J Neurosci. 2006 Jan 4;26(1):63-72
pubmed: 16399673
Curr Pharm Des. 2009;15(22):2550-9
pubmed: 19689327
Neuropsychopharmacology. 2001 Oct;25(4):455-67
pubmed: 11557159
Proc Biol Sci. 2006 Feb 22;273(1585):503-11
pubmed: 16615219
J Neurosci. 2011 Jun 1;31(22):8259-70
pubmed: 21632947
Nat Rev Neurosci. 2012 Apr 13;13(5):336-49
pubmed: 22498897
Hum Brain Mapp. 2005 May;25(1):46-59
pubmed: 15846822
Neuroimage. 2012 Jan 2;59(1):431-8
pubmed: 21810475
Neuroimage. 2012 Mar;60(1):623-32
pubmed: 22233733
Sci Rep. 2017 Oct 13;7(1):13187
pubmed: 29030624
JAMA Psychiatry. 2013 Aug;70(8):783-92
pubmed: 23739835
CNS Drugs. 2004;18(4):251-67
pubmed: 15015905
Neuroimage. 2014 Jul 15;95:287-304
pubmed: 24657353
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Dialogues Clin Neurosci. 2013 Sep;15(3):339-49
pubmed: 24174905
Neuroimage. 2012 Feb 1;59(3):2142-54
pubmed: 22019881
Brain. 2008 Apr;131(Pt 4):945-61
pubmed: 18299296
Neuroimage. 1999 Apr;9(4):407-15
pubmed: 10191169
Trends Cogn Sci. 2013 Dec;17(12):641-7
pubmed: 24238779
Am J Psychiatry. 2011 Dec;168(12):1311-7
pubmed: 21768612
JAMA Psychiatry. 2013 Aug;70(8):780-2
pubmed: 23739868
Phys Rev Lett. 2001 Nov 5;87(19):198701
pubmed: 11690461
JAMA Psychiatry. 2013 Sep;70(9):903-12
pubmed: 23824230
Neurosci Lett. 2009 Jul 10;458(1):1-5
pubmed: 19442867
JAMA Psychiatry. 2015 Jan;72(1):5-13
pubmed: 25372846